ZIOPHARM Oncology, Inc. (ZIOP) Technical Charts Have Buy Or Sell signals?

Looking into the technicals, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has scored 40% Buy indication. The stock is also flashing a Buy from the Barchart TrendSpotter trading system. Traders hoping to speculate on the ZIOP’s short-term trajectory should know that short terms indicators for the stock averaged 60% Buy with an average daily trading volume over the past 20 days at 1997945 shares. ZIOP stock has overall a 0.25% Buy signal considering medium term indicators and the 50-day average daily volume remained almost 1578700 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was 1355591 shares, is 0% Hold on the basis of long term indicators.

The share price is currently staying around the first support level of $2.99. Below this, the next support is placed in the zone of $2.79. Till the time, the ZIOP stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 68.68 on daily chart, which may remain a cause for concern. If the price breaks below $2.79 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $3.32 mark may result into a pull-back move towards $3.45 level.

ZIOPHARM Oncology, Inc. (ZIOP) is projected to climb by 40.63 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $5.5-month high price target. This represents a whopping 71.88 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $5, which represents a return potential of 56.25 percent when compared to the closing price of the stock of $3.2 on Friday, November 16. The lowest price target for the stock is $3 — slightly more than -6.25 percent from ZIOP’s current share price.

Here’s a rundown of insider trading activity for sense of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP). The earliest insider trade took place on 11/08/2017. Mauney David M Md gathered a total of 4.27 thousand shares of company at average share price of $4.68. The total for the purchase was set at $19.98 thousand. After this transaction, the EVP and Chief Business Officer account balance stood at 58.66 thousand shares. The stock lost -31.62 percent since that insider purchase. On 11/08/2017, Cooper Laurence James Neil, CEO, purchased 6.44 thousand shares at a price per share of $4.68. This added 30.14 thousand shares to the insider’s fortune and the stock saw a -31.62 percent retreat in value since the news became public. This transaction left 1.08 million shares in the CEO account. On 11/19/2015, COO, CLO, and Secretary Belbel Caesar J performed a sale transaction worth $1.97 million. This sale at $12.84 each has eliminated 153.33 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -75.08 percent decrease since the transaction was reported. The insider now is left with 59.2 thousand shares remaining in the account. Lebel Francois, who performs the Executive Vice President R&D job, sold 50 thousand shares for $506 thousand. The disposal occurred on 06/09/2015 was priced at $10.12 per share. The share price plunged -68.38 percent since the reporting date. Lebel Francois now left with a stake of 0 thousand ZIOP stock worth $0 thousand after the insider selling.

ZIOP shares accumulated 0.12 points or 3.9 percent on Friday to $3.2 with a heavy trade volume of 3.644 million shares. After opening the session at $3.08, the shares went as high as $3.24 and as low as $2.91, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $456 million and now has 142.38 million shares outstanding. ZIOPHARM Oncology, Inc. (ZIOP) stock has gained 34.45 percent of market value in 21 trading days.

Analysts at Raymond James upped their rating on shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) from Mkt Perform to Outperform in their opinion released on November 15. JP Morgan analysts have downgraded their rating of ZIOP stock from Neutral to Underweight in a separate flash note to investors on June 18.

ZIOP stock has a trailing 3-year beta of 1.79, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.54 a share in the trailing twelve months. The stock’s value has fallen -22.71 percent year to date (YTD) against a decline of -32.49 percent in 12 month’s time. The company’s shares still trade -38.99 percent away from its 1-year high of $5.24 and 68.42 percent up from 52-week low of $1.90. The average consensus rating on the company is 2.8, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.

Shares of ZIOPHARM Oncology, Inc. (ZIOP) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry ZIOP operates in has an average P/E of 79.36. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 268.01 on the Price-to-Sales ratio. Compare this with the industry average P/S of 217.51. 0 percent is the gross profit margin for ZIOPHARM Oncology, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

ZIOP will be declaring its Q4 financial results on February 28. Analysts are forecasting revenue to suffer decline of -33 percent to $1.07M in the next fiscal quarter, while earnings are seen soaring by nearly -15.38 percent to -$0.11 per share. History has shown that shares in ZIOPHARM Oncology, Inc. have gone up on 17 different earnings reaction days and are predicted to add 0.04 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.13 per share, worse than the -$0.11, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $0, worse than the $930000 analysts expected. Earnings are estimated to increase by 59.5 percent this year, 37.3 percent next year and continue to increase by 0 percent annually for the next 5 years.